Pfizer Biontech vaccine, in the vials in the USA there are more doses than expected. This is what will happen

Following the news that two adverse reactions were recorded in Alaska after the administration of the Pfizer vaccine comes the one of the company’s involuntary Christmas gift: from its vials it is possible to extract more than five doses, up to six or seven, increasing the potential of the first supplies by up to 40%. A discovery made by those who run it, according to the US media. The Food and Drug Administration (FDA), which must decide shortly whether to authorize the other vaccine developed with the messenger RNA technique produced by Moderna, is in contact with the pharmaceutical company but in the meantime has already authorized the use of the entire vaccine . vial, abut it advises not to mix the remains of different vials. This is while the US government is negotiating with Pfizer to buy tens of millions of additional doses in the spring. In the United States, the threshold of 17 million cases has been exceeded. According to tracking by Johns Hopkins University, 17,000,408 cases of infection have been confirmed in the country since the start of the pandemic, with 307,770 confirmed deaths.

The Pfizer-Biontech vaccine was the first approved in the world and the first inoculated. The founder of the German company in a meeting with the German Chancellor Angela Merkel and with the Minister of Health he is optimistic about the future: “We are confident that next winter we will be able to live a normal situation, without having to resort to more confinement,” says Ugur Sahin, number one at Biontech. “We hope that in the coming days we can distribute the vaccines in all countries,” he continued, underlining that three factors have allowed the success of Biontech in obtaining an anticovide vaccine “in just 11 months”. “Long-term research”, “a fantastic team”, with scientists from different countries around the world, who worked “even on weekends”, and “international collaboration”. “We understood that our small business alone could not provide billions of doses of the vaccine,” Sahin explained, hence the choice to collaborate “with a partner like Pfizer and a host of other companies.”